# Preventing Inhibitor Recurrence Indefinitely

> **NCT04621916** · PHASE4 · UNKNOWN · sponsor: **Children's Hospital Los Angeles** · enrollment: 52 (estimated)

## Conditions studied

- Hemophilia A
- Immune Tolerance

## Interventions

- **DRUG:** FVIII
- **DRUG:** Emicizumab

## Key facts

- **NCT ID:** NCT04621916
- **Lead sponsor:** Children's Hospital Los Angeles
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2020-09-21
- **Primary completion:** 2024-09-20
- **Final completion:** 2025-04-20
- **Target enrollment:** 52 (ESTIMATED)
- **Last updated:** 2023-10-05

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04621916

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04621916, "Preventing Inhibitor Recurrence Indefinitely". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT04621916. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*